News | May 02, 2026
FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
